

Campbell McInnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5073256/publications.pdf>

Version: 2024-02-01

32
papers

1,447
citations

471509

17
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

2081
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtual screening strategies in drug discovery. <i>Current Opinion in Chemical Biology</i> , 2007, 11, 494-502.	6.1	372
2	Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS. <i>Structure</i> , 2003, 11, 399-410.	3.3	115
3	Progress in the Discovery of Polo-like Kinase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 181-197.	2.1	114
4	Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. , 2006, 2, 608-617.		92
5	PLK1 as an oncology target: current status and future potential. <i>Drug Discovery Today</i> , 2011, 16, 619-625.	6.4	89
6	Progress in the evaluation of CDK inhibitors as anti-tumor agents. <i>Drug Discovery Today</i> , 2008, 13, 875-881.	6.4	65
7	Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. <i>Biochemical Pharmacology</i> , 2009, 77, 1561-1571.	4.4	55
8	Quantification of the Effects of Ionic Strength, Viscosity, and Hydrophobicity on Protein-Ligand Binding Affinity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 931-936.	2.8	55
9	Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 2735.	2.8	53
10	Insights into Cyclin Groove Recognition. <i>Structure</i> , 2003, 11, 1537-1546.	3.3	52
11	RAF kinase dimerization: implications for drug discovery and clinical outcomes. <i>Oncogene</i> , 2020, 39, 4155-4169.	5.9	44
12	REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors. <i>ChemBioChem</i> , 2006, 7, 1909-1915.	2.6	40
13	Peptidomimetic Design of CDK Inhibitors Targeting the Recruitment Site of the Cyclin Subunit. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 57-69.	7.0	39
14	Current assessment of polo-like kinases as anti-tumor drug targets. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 773-789.	5.0	39
15	Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3886-3897.	6.4	23
16	Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1683-1692.	4.1	22
17	Structural and Functional Analysis of Cyclin D1 Reveals p27 and Substrate Inhibitor Binding Requirements. <i>ACS Chemical Biology</i> , 2010, 5, 1169-1182.	3.4	19
18	Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1573-1582.	6.4	19

#	ARTICLE	IF	CITATIONS
19	Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-Site: structural variants of the C-Terminal Phe. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2501-2505.	2.2	18
20	Truncation and Optimisation of Peptide Inhibitors of Cyclin-Dependent Kinase 2-Cyclinâ€¦A Through Structure-Guided Design. <i>ChemMedChem</i> , 2009, 4, 1120-1128.	3.2	17
21	A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3420-3433.	6.4	14
22	Iterative Conversion of Cyclin Binding Groove Peptides into Druglike CDK Inhibitors with Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 433-442.	6.4	12
23	Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 616-622.	3.0	11
24	The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. <i>Cell Chemical Biology</i> , 2018, 25, 1107-1116.e4.	5.2	11
25	Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. <i>ChemMedChem</i> , 2020, 15, 1058-1066.	3.2	10
26	Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9916-9925.	6.4	9
27	Catch the Kinase Conformer. <i>Chemistry and Biology</i> , 2006, 13, 693-694.	6.0	8
28	Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimerâ€™s disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5573-5579.	2.2	8
29	Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. <i>Protein Expression and Purification</i> , 2015, 113, 8-16.	1.3	7
30	Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3754-3760.	2.2	6
31	Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113926.	5.5	6
32	Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. <i>Journal of Visualized Experiments</i> , 2015, , e52441.	0.3	2